← All trials
NCT06275035
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 22, 2024
- Primary completion
- Jan 31, 2026
- Completion date
- Jan 31, 2031
- First posted
- Feb 23, 2024
- Last posted
- Mar 1, 2024
- Enrollment
- 101
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tata Memorial HospitalLead sponsor
- Tata Memorial HospitalSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.